MN1 (gene)
MN1 is a gene found on human chromosome 22, with gene map locus 22q12.3-qter.[1] Its official full name is meningioma (disrupted in balanced translocation) 1 because it is disrupted by a balanced translocation (4;22) in a meningioma.
Function
Function
MN1 is a transcription coregulator that enhances or represses RAR/RXR-mediated gene transcription through interaction with RAC3 and p300.[2] MN1 also acts as a coactivator of the vitamin D receptor.[3]
Clinical significance
Clinical significance
Its inactivation may be part of the cause of certain meningiomas.[1] A potential link to leukemia[4] including acute myeloid leukemia[5] has also been described.
References
References
- ↑ 1.0 1.1 Lekanne Deprez RH, Riegman PH, Groen NA, Warringa UL, van Biezen NA, Molijn AC, Bootsma D, de Jong PJ, Menon AG, Kley NA (April 1995). “Cloning and characterization of MN1, a gene from chromosome 22q11, which is disrupted by a balanced translocation in a meningioma”. Oncogene. 10 (8): 1521–8. PMID 7731706.
- ↑ van Wely KH, Molijn AC, Buijs A, Meester-Smoor MA, Aarnoudse AJ, Hellemons A, den Besten P, Grosveld GC, Zwarthoff EC (February 2003). “The MN1 oncoprotein synergizes with coactivators RAC3 and p300 in RAR-RXR-mediated transcription”. Oncogene. 22 (5): 699–709. doi:10.1038/sj.onc.1206124. PMID 12569362.
- ↑ Sutton AL, Zhang X, Ellison TI, Macdonald PN (September 2005). “The 1,25(OH)2D3-regulated transcription factor MN1 stimulates vitamin D receptor-mediated transcription and inhibits osteoblastic cell proliferation”. Mol. Endocrinol. 19 (9): 2234–44. doi:10.1210/me.2005-0081. PMID 15890672.
- ↑ Buijs A, Sherr S, van Baal S, et al. (April 1995). “Translocation (12;22) (p13;q11) in myeloproliferative disorders results in fusion of the ETS-like TEL gene on 12p13 to the MN1 gene on 22q11”. Oncogene. 10 (8): 1511–9. PMID 7731705.
- ↑ Grosveld GC (2007). “MN1, a novel player in human AML”. Blood Cells Mol. Dis. 39 (3): 336–9. doi:10.1016/j.bcmd.2007.06.009. PMC 2387274. PMID 17698380.
Further reading
Further reading
- Kawagoe H, Grosveld GC (2005). “MN1-TEL myeloid oncoprotein expressed in multipotent progenitors perturbs both myeloid and lymphoid growth and causes T-lymphoid tumors in mice”. Blood. 106 (13): 4278–86. doi:10.1182/blood-2005-04-1674. PMC 1895241. PMID 16081688.
- Schroeder T, Czibere A, Zohren F, et al. (2009). “Meningioma 1 gene is differentially expressed in CD34 positive cells from bone marrow of patients with myelodysplastic syndromes with the highest expression in refractory anemia with excess of blasts and secondary acute myeloid leukemia”. Leuk. Lymphoma. 50 (6): 1043–6. doi:10.1080/10428190902913591. PMID 19391034.
- Meester-Smoor MA, Janssen MJ, Grosveld GC, et al. (2008). “MN1 affects expression of genes involved in hematopoiesis and can enhance as well as inhibit RAR/RXR-induced gene expression”. Carcinogenesis. 29 (10): 2025–34. doi:10.1093/carcin/bgn168. PMC 3202306. PMID 18632758.
- Carella C, Bonten J, Sirma S, et al. (2007). “MN1 overexpression is an important step in the development of inv(16) AML”. Leukemia. 21 (8): 1679–90. doi:10.1038/sj.leu.2404778. PMID 17525718.
- Heuser M, Argiropoulos B, Kuchenbauer F, et al. (2007). “MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML”. Blood. 110 (5): 1639–47. doi:10.1182/blood-2007-03-080523. PMID 17494859.
- Langer C, Marcucci G, Holland KB, et al. (2009). “Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study”. J. Clin. Oncol. 27 (19): 3198–204. doi:10.1200/JCO.2008.20.6110. PMC 2716941. PMID 19451432.
- Barbe L, Lundberg E, Oksvold P, et al. (2008). “Toward a confocal subcellular atlas of the human proteome”. Mol. Cell. Proteomics. 7 (3): 499–508. doi:10.1074/mcp.M700325-MCP200. PMID 18029348.
- Kawagoe H, Grosveld GC (2005). “Conditional MN1-TEL knock-in mice develop acute myeloid leukemia in conjunction with overexpression of HOXA9”. Blood. 106 (13): 4269–77. doi:10.1182/blood-2005-04-1679. PMC 1895240. PMID 16105979.
- Kandilci A, Grosveld GC (2009). “Reintroduction of CEBPA in MN1-overexpressing hematopoietic cells prevents their hyperproliferation and restores myeloid differentiation”. Blood. 114 (8): 1596–606. doi:10.1182/blood-2009-02-205443. PMC 2731639. PMID 19561324.
- Trynka G, Zhernakova A, Romanos J, et al. (2009). “Coeliac disease-associated risk variants in TNFAIP3 and REL implicate altered NF-kappaB signalling”. Gut. 58 (8): 1078–83. doi:10.1136/gut.2008.169052. PMID 19240061.
- Gastier JM, Brody T, Pulido JC, et al. (1996). “Development of a screening set for new (CAG/CTG)n dynamic mutations”. Genomics. 32 (1): 75–85. doi:10.1006/geno.1996.0078. PMID 8786123.
- Collins JE, Wright CL, Edwards CA, et al. (2004). “A genome annotation-driven approach to cloning the human ORFeome”. Genome Biol. 5 (10): R84. doi:10.1186/gb-2004-5-10-r84. PMC 545604. PMID 15461802.
- Beausoleil SA, Jedrychowski M, Schwartz D, et al. (2004). “Large-scale characterization of HeLa cell nuclear phosphoproteins”. Proc. Natl. Acad. Sci. U.S.A. 101 (33): 12130–5. doi:10.1073/pnas.0404720101. PMC 514446. PMID 15302935.
- Meester-Smoor MA, Molijn AC, Zhao Y, et al. (2007). “The MN1 oncoprotein activates transcription of the IGFBP5 promoter through a CACCC-rich consensus sequence”. J. Mol. Endocrinol. 38 (1–2): 113–25. doi:10.1677/jme.1.02110. PMID 17242174.
- Buijs A, Sherr S, van Baal S, et al. (1995). “Translocation (12;22) (p13;q11) in myeloproliferative disorders results in fusion of the ETS-like TEL gene on 12p13 to the MN1 gene on 22q11”. Oncogene. 10 (8): 1511–9. PMID 7731705.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH